Study characteristics |
Methods |
Prospective cohort |
Participants |
59 children aged 1 to 6 years (mean about 2 years) |
Interventions |
MMR vaccine (Merck Institute for Therapeutic Research)
versus
Mumps ‐ rubella vaccine (Merck Institute for Therapeutic Research)
versus
Rubella vaccine (Merck ‐ Meruvax HPV 77‐DE5)
No information about doses and schedule |
Outcomes |
Temperature (37.2 to 38.2 °C; 38.3 to 39.3 °C; over 39.4 °C), lymphadenopathy, enanthema, conjunctivitis, rash, complaints ‐ any (up to 60 days). Follow‐up 7 to 15 days |
Funding Source |
Mixed (government and pharmaceutical industry) |
Notes |
|
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
PCS/RCS ‐ exposed cohort selection |
High risk |
There was insufficient information. |
PCS/RCS ‐ non‐exposed cohort selection |
High risk |
There was insufficient information. |
PCS/RCS ‐ comparability |
High risk |
No adjustment for confounding |
PCS/RCS ‐ assessment of outcome |
High risk |
There was insufficient information. |
Summary Risk of Bias assessment |
High risk |
We had concerns regarding multiple domains such that our confidence in the result is substantially lowered. |